Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature

QIN Youfa; ZHANG Qing; LIU Li

doi:10.3969/j.issn.1006-0111.2016.02.022

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To investigate countermeasures and effects of clinical pharmacists participating in the treatment for fluconazole-exposure candidemia, and to provide reference for infectious control in the clinic. Methods Clinical pharmacists used their professional knowledge and suggested utilizing micafungin to treat candidemia, when voriconazole was ineffective in a patient with candidemia and fluconazole exposure history. Results The patient's candida bloodstream infection was finally controlled. Clinical pharmacists were highly complimented from the doctors, nurses and patients. Conclusion Micafungin is effective in treatment of candidemia with a recent(<30 days) fluconazole exposure history. The participation of clinical pharmacists is helpful to develop individual medicinal therapy in clinical treatment and can improve therapeutic effects.

Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature

1. Department of Pharmacy, Third people's Hospital of Dongguan, Dongguan 523326, China

2. Department of Pharmacy, Nanfang Hospital Affiliated to Southern Medical University, Guangzhou 510515, China

3. Department of Pharmacy, Suizhou Hospital of Hubei Medicine College, Suizhou 441300, China

Received Date: 2014-08-02

Rev Recd Date: 2015-08-28

Key words:

Abstract: Objective To investigate countermeasures and effects of clinical pharmacists participating in the treatment for fluconazole-exposure candidemia, and to provide reference for infectious control in the clinic. Methods Clinical pharmacists used their professional knowledge and suggested utilizing micafungin to treat candidemia, when voriconazole was ineffective in a patient with candidemia and fluconazole exposure history. Results The patient's candida bloodstream infection was finally controlled. Clinical pharmacists were highly complimented from the doctors, nurses and patients. Conclusion Micafungin is effective in treatment of candidemia with a recent(<30 days) fluconazole exposure history. The participation of clinical pharmacists is helpful to develop individual medicinal therapy in clinical treatment and can improve therapeutic effects.

HTML

Reference (15)

[1]	Pfaller MA, Diekema DJ.Epidemiology of invasive candidiasis:a persistent public health problem[J].Clin Microbiol Rev, 2007, 20(1):133-163.
[2]	Anunnatsiri S, Chetchotisakd P, Mootsikapun P.Fungemia in non-HIV-infected patients:a five-year review.[J].Int J Infect Dis, 2009, 13(1):90-96.
[3]	Playford EG, Lipman J, Sorrell TC.Management of invasive candidiasis in the intensive care unit.[J].Drugs, 2010, 70(7):823-839.
[4]	Pappas PG, Kauffman CA, Andes D,et al.Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Diseases Society of America.[J].Clin Infect Dis, 2009, 48(5):503-535.
[5]	Ostrosky-Zeichner L, Pappas PG.Invasive candidiasis in the intensive care unit[J].Crit Care Med, 2006, 34(3):857-863.
[6]	Sanford JP. 热病:桑福德抗微生物治疗指南[M].北京:中国协和医科大学出版社,2011:73.
[7]	Prasad PA, Fisher BT, Coffin SE,et al.Pediatric risk factors for candidemia secondary to and species[J].J Pediatric Infect Dis Soc, 2013, 2(3):263-266.
[8]	Shah DN, Yau R, Lasco TM,et al.Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia[J].Antimicrob Agents Chemother, 2012, 56(6):3239-3243.
[9]	Borst A, Raimer MT, Warnock DW,et al.Rapid acquisition of stable azole resistance by candida glabrata isolates obtained before the clinical introduction of fluconazole[J].Antimicrob Agents Chemother, 2005, 49(2):783-787.
[10]	Lortholary O, Desnos-Ollivier M, Sitbon K,et al.Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia:a prospective multicenter study involving 2,441 patients[J].Antimicrob Agents Chemother, 2011, 55(2):532-538.
[11]	Magill SS, Shields C, Sears CL,et al.Triazole cross-resistance among Candida spp.:case report, occurrence among bloodstream isolates, and implications for antifungal therapy[J].J Clin Microbiol, 2006, 44(2):529-535.
[12]	Chang TP, Ho MW, Yang YL,et al.Distribution and drug susceptibilities of Candida species causing candidemia from a medical center in central Taiwan[J].J Infect Chemother, 2013.
[13]	Pfaller MA, Diekema DJ, Ostrosky-Zeichner L,et al.Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin:analysis and proposal for interpretive MIC breakpoints[J].J Clin Microbiol, 2008, 46(8):2620-2629.
[14]	Messer SA, Diekema DJ, Boyken L,et al.Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.[J].J Clin Microbiol, 2006, 44(2):324-326.
[15]	胡晶,商洪才,李晶,等.血必净注射液治疗脓毒症的系统评价[J].解放军医学杂志,2010(1):9-12.

Message Board

Clinical analysis of 1 case of micafungin treatment: fluconazole-exposed candidemia and review of related literature

doi: 10.3969/j.issn.1006-0111.2016.02.022

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views